/ MRK

/ Earnings

Merck & Co. (MRK) Reports Better than Expected Results for First-Quarter 2025

Merck's Q1 2025 results show a slight decrease in total sales but highlight growth in key segments.

April 24, 2025

President Trump's proposed tariffs on imported pharmaceuticals could significantly impact global trade.

April 09, 2025

MSD's new injectable Keytruda formulation offers similar effectiveness to the intravenous version, potentially halving treatment time.

March 28, 2025

Despite falling short of anticipated non-GAAP EPS at $1.72, Merck's revenue exceeded expectations.

February 04, 2025

Merck's third-quarter financial performance in 2024 showcased robust worldwide sales growth of 4%, reaching $16.7 billion.

October 31, 2024